Abstract
Background COVID-19 outbreaks are still occurring in English care homes despite the non-pharmaceutical interventions (NPIs) in place.
Methods We developed a stochastic compartmental model to simulate the spread of SARS-CoV-2 within an English care home. We quantified the outbreak risk under the NPIs already in place, the role of community prevalence in driving outbreaks, and the relative contribution of all importation routes into the care home. We also considered the potential impact of additional control measures, namely: increasing staff and resident testing frequency, using lateral flow antigen testing (LFD) tests instead of PCR, enhancing infection prevention and control (IPC), increasing the proportion of residents isolated, shortening the delay to isolation, improving the effectiveness of isolation, restricting visitors and limiting staff to working in one care home.
Findings The model suggests that importation of SARS-CoV-2 by staff, from the community, is the main driver of outbreaks, that importation by visitors or from hospitals is rare, and that the past testing strategy (monthly testing of residents and daily testing of staff by PCR) likely provides negligible benefit in preventing outbreaks. Daily staff testing by LFD was 39% (95% 18-55%) effective in preventing outbreaks at 30 days compared to no testing.
Interpretation Increasing the frequency of testing in staff and enhancing IPC are important to preventing importations to the care home. Further work is needed to understand the impact of vaccination in this population, which is likely to be very effective in preventing outbreaks.
Funding The National Institute for Health Research, European Union Horizon 2020, Canadian Institutes of Health Research, French National Research Agency, UK Medical Research Council. The World Health Organisation funded the development of the COS-LTCF Shiny application.
Evidence before this study Care homes have been identified as being at increased risk of COVID-19 outbreaks, and a number of modelling studies have considered the transmission dynamics of SARS-CoV-2 in this setting. We searched the PubMed database and bioRxiv and medRxiv’s COVID-19 SARS-CoV-2 preprints for English-language articles on the 11th May 2021, with the search terms (“COVID-19” OR “SARS-CoV-2” OR “coronavirus”) AND (“care home” OR “LTCF” OR “long term care facility” OR “nursing home”) AND (“model”). In addition to these searches, we identified articles relevant to this work through informal networks. These searches returned 87 studies, of which 12 explicitly modelled SARS-CoV-2 transmission within care homes and explored the effectiveness of non-pharmaceutical interventions in these settings. These studies employed a number of modelling approaches (agent-based and compartmental models) and considered various strategies for mitigating epidemic spread within care homes. Only one of these studies modelled care homes in England, but didn’t consider individual care homes as separate entities (transmission between residents in separate facilities was equally likely as within one facility) and only modelled one intervention within the care home: the effect of restricting visitors. Another study modelled a different type of long-term care facility, a rehabilitation facility in France. Other studies modelled care homes in Canada, Scotland, and the US. These modelled care homes were larger than the average English care home. Only one study included importation of SARS-CoV-2 to care homes from hospitals through resident hospitalisation.
Added value of this study We developed a stochastic compartmental model describing the transmission dynamics of SARS-CoV-2 within English care homes. This study is the first to assess the relative importance of all SARS-CoV-2 importation routes to care homes (including resident hospitalisation) and to quantify the impact of a range of non-pharmaceutical interventions against SARS-CoV-2 particularly for English care homes. We found that community prevalence, through staff importations, was the main driver of outbreaks in care homes at 30 days, not importation from hospital visits nor by visitors. In line with this, we found daily testing of staff to be the most effective testing strategy in preventing outbreaks. We show the previous testing strategy (PCR testing residents once every 28 days and staff once a week) to be ineffective in preventing outbreaks and suggest that more frequent testing of staff is required. Restricting visitors bore little effect on the probability of an outbreak occurring by day 30. Interventions focusing on decreasing the transmission of SARS-CoV-2 in the care home were the most effective in reducing the frequency of outbreaks. We provide a Shiny application for users to explore alternative care home characteristics, outbreak characteristics and interventions.
Implications of all the available evidence Preventing the importation of SARS-CoV-2 to care homes from the community through staff is key to preventing outbreaks. Infection prevention and control (IPC) measures targeting transmission within the care home and frequent testing of staff, ideally daily, are the most effective strategies considered. Many care homes in England are currently unable to meet the additional workload daily testing would entail, therefore additional support should be considered to enable these measures. Allowing visitors should be considered given their general positive contribution to residents’ physical and mental health and likely negligible contribution to outbreaks.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
AR acknowledges funding from the National Institute for Health Research (grant: PR-OD-1017-20002). RCB acknowledges funding from the European Union Horizon 2020 Research and Innovation programme, project EpiPose (101003688), throughout the duration of the study. DS is supported by a Canadian Institutes of Health Research Doctoral Foreign Study Award (Funding Reference Number 164263) and the French National Research Agency project SPHINX-17-CE36-0008-01. GMK is supported by the UK Medical Research Council (grant: MR/P014658/1). We would like to thank Ian Hall, as well as the rest of the Care Home Working Group for helpful conversations as well as William Laing, Claire Goodman, Des Kelly and Julie Robotham for their insight; and Carl Pearson and Joel Hellewell for their helpful inputs. This work uses data provided by patients and collected by the NHS as part of their care and support. The development of the Shiny application COS-LTCF was funded by the World Health Organization.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data used for this modelling work was provided by NHS England.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Working group members are listed separately
Members of the Centre for Mathematical Modelling of Infectious Diseases COVID-19 modelling working group (random order): Carl A B Pearson, Thibaut Jombart, Simon R Procter, Yung-Wai Desmond Chan, Graham Medley, Joel Hellewell, Billy J Quilty, Yang Liu, Stefan Flasche, Sam Abbott, Rosalind M Eggo, Rachel Lowe, Yalda Jafari, Christopher I Jarvis, Naomi R Waterlow, James D Munday, Amy Gimma, Nikos I Bosse, Petra Klepac, Akira Endo, Adam J Kucharski, Rosanna C Barnard, C Julian Villabona-Arenas, Sebastian Funk, Kevin van Zandvoort, W John Edmunds, William Waites, Emily S Nightingale, Sophie R Meakin, Frank G Sandmann, Fabienne Krauer, Nicholas G. Davies, Alicia Showering, Samuel Clifford, Katherine E. Atkins, Matthew Quaife, Kaja AbbasTimothy W Russell, Fiona Yueqian Sun, Mark Jit, Mihaly Koltai, Kiesha Prem, Jiayao Lei, Anna M Foss, Jack Williams, Kathleen O’Reilly, Damien C Tully, Hamish P Gibbs, Oliver Brady
CMMID COVID-19 modelling working group funding statements: CABP (B&MGF: NTD Modelling Consortium OPP1184344, FCDO/Wellcome Trust: Epidemic Preparedness Coronavirus research programme 221303/Z/20/Z), TJ (Global Challenges Research Fund: ES/P010873/1, UK Public Health Rapid Support Team, NIHR: Health Protection Research Unit for Modelling Methodology HPRU-2012-10096, UK MRC: MC_PC_19065), SRP(B&MGF: INV-016832), GFM (B&MGF: NTD Modelling Consortium OPP1184344), JH (Wellcome Trust: 210758/Z/18/Z), BJQ (NIHR: 16/137/109, NIHR: 16/136/46, B&MGF: OPP1139859), YL (B&MGF: INV-003174, NIHR: 16/137/109, European Commission: 101003688, UK MRC: MC_PC_19065), SFlasche (Wellcome Trust: 208812/Z/17/Z), SA (Wellcome Trust: 210758/Z/18/Z), RME (HDR UK: MR/S003975/1, UK MRC: MC_PC_19065, NIHR: NIHR200908), RL (Royal Society: Dorothy Hodgkin Fellowship), YJ UKRI: MR/V028456/1, CIJ (Global Challenges Research Fund: ES/P010873/1), NRW(MRC: MR/N013638/1), JDM (Wellcome Trust: 210758/Z/18/Z), AG (European Commission: 101003688), NIB (HPRU: NIHR200908), PK (Royal Society: RP\EA\180004, European Commission: 101003688), AE (Nakajima Foundation), AJK (Wellcome Trust: 206250/Z/17/Z, NIHR: NIHR200908), RCB (European Commission: 101003688), SFunk (Wellcome Trust: 210758/Z/18/Z), KvZ (Elrha R2HC/UK FCDO/Wellcome Trust/NIHR, FCDO/Wellcome Trust: Epidemic Preparedness Coronavirus research programme 221303/Z/20/Z), WJE (European Commission: 101003688, UK MRC: MC_PC_19065, NIHR: PR-OD-1017-20002), WW (MRC: MR/V027956/1), ESN (B&MGF: OPP1183986), SRM (Wellcome Trust: 210758/Z/18/Z), FGS (NIHR: NIHR200929), FK (Innovation Fund: 01VSF18015, Wellcome Trust: UNS110424), NGD (UKRI Research England, NIHR: NIHR200929, UK MRC: MC_PC_19065), SC (Wellcome Trust: 208812/Z/17/Z, UK MRC: MC_PC_19065), MQ (ERC Starting Grant: #757699, B&MGF: INV-001754), KA (BMGF: INV-016832; OPP1157270), TWR (Wellcome Trust: 206250/Z/17/Z), FYS (NIHR: 16/137/109), MJ (B&MGF: INV-003174, NIHR: 16/137/109, NIHR: NIHR200929, European Commission: 101003688), MK (Wellcome Trust 221303/Z/20/Z), KP (B&MGF: INV-003174, European Commission: 101003688), JYL Gates (INV-003174), KO’R (B&MGF: OPP1191821), HPG (EDCTP2: RIA2020EF-2983-CSIGN, UK DHSC/UK Aid/NIHR: PR-OD-1017-20001), OJB (Wellcome Trust: 206471/Z/17/Z)
Data Availability
Available upon request.
